FFA
GPCR icon

Fairfield Financial Advisors’s Structure Therapeutics GPCR Stock Holding History

Fairfield Financial Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-59
Closed -$1.6K – 116
2024
Q4 		$1.6K Hold
59
– – ﹤0.01% 243
2024
Q3 		$2.59K Hold
59
– – ﹤0.01% 265
2024
Q2 		$2.32K Buy
+59
New +$2.42K ﹤0.01% 261
2023
Q4 		$2.4K Buy
+59
New +$3.38K ﹤0.01% 288

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Fairfield Financial Advisors's GPCR Position: Q1 2025 in Review

Fairfield Financial Advisors sold out of Structure Therapeutics (GPCR) in Q1 2025, closing a stake of 59 shares — an estimated $1.6K sold.

Fairfield Financial Advisors first reported a position in GPCR in Q4 2023 and held it in 4 quarters. The position peaked at $2.59K in Q3 2024. 150 funds tracked by Wall St. Rank hold GPCR as of Q1 2025.

  • Fairfield Financial Advisors reported no remaining Structure Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Fairfield Financial Advisors sold 59 Structure Therapeutics shares in Q1 2025, an estimated $1.6K.
  • Fairfield Financial Advisors first reported a position in Structure Therapeutics in Q4 2023 and held it in 4 quarters.
  • Fairfield Financial Advisors's Structure Therapeutics position peaked at $2.59K in Q3 2024.
  • 150 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2025.

Based on Fairfield Financial Advisors's 13F filing for Q1 2025, filed 9 May 2025.